Inogen Inc. (NASDAQ:INGN) CEO Raymond Huggenberger sold 7,089 shares of the company’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $56.24, for a total transaction of $398,685.36. Following the completion of the transaction, the chief executive officer now directly owns 8,342 shares of the company’s stock, valued at approximately $469,154.08. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Raymond Huggenberger also recently made the following trade(s):
- On Monday, August 15th, Raymond Huggenberger sold 20,747 shares of Inogen stock. The stock was sold at an average price of $57.48, for a total transaction of $1,192,537.56.
Shares of Inogen Inc. (NASDAQ:INGN) traded down 0.54% on Wednesday, hitting $57.46. 105,210 shares of the company were exchanged. The firm’s 50-day moving average is $59.11 and its 200-day moving average is $52.39. The stock has a market capitalization of $1.15 billion, a PE ratio of 84.50 and a beta of 0.88. Inogen Inc. has a 52-week low of $28.81 and a 52-week high of $61.87.
Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. The company earned $54.57 million during the quarter, compared to the consensus estimate of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The firm’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 earnings per share. Equities research analysts predict that Inogen Inc. will post $0.63 earnings per share for the current year.
Several research analysts recently weighed in on INGN shares. Zacks Investment Research downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th. Stifel Nicolaus downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Friday, August 5th. They noted that the move was a valuation call. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $64.00 target price (up previously from $58.00) on shares of Inogen in a report on Sunday, August 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Inogen in a report on Wednesday, July 13th. They set an “overweight” rating for the company. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Inogen presently has a consensus rating of “Buy” and a consensus price target of $58.50.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Capstone Asset Management Co. acquired a new position in Inogen during the second quarter worth about $229,000. BNP Paribas Arbitrage SA increased its position in Inogen by 102.2% in the second quarter. BNP Paribas Arbitrage SA now owns 4,617 shares of the medical technology company’s stock worth $231,000 after buying an additional 2,334 shares in the last quarter. LPL Financial LLC acquired a new position in Inogen during the first quarter worth about $1,118,000. A.R.T. Advisors LLC increased its position in Inogen by 20.3% in the first quarter. A.R.T. Advisors LLC now owns 15,415 shares of the medical technology company’s stock worth $693,000 after buying an additional 2,600 shares in the last quarter. Finally, Springbok Capital Management LLC increased its position in Inogen by 2.5% in the first quarter. Springbok Capital Management LLC now owns 4,100 shares of the medical technology company’s stock worth $184,000 after buying an additional 100 shares in the last quarter.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.